PRESS DIGEST-Financial Times - September 17

By Reuters News

Sept 17 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Headlines

  • Breast cancer drug approved after UK pharma deal with Trump

  • Andy Burnham considers plan to give mayors greater oversight of water companies

  • Mark Walter and Todd Boehly sell Chelsea FC stakes to Clearlake for £950 million

  • Vodafone takes up to €1.1 billion hit from Drahi's German broadband deal

Overview

  • Britain's medicines watchdog approved AstraZeneca AZN.L and Daiichi Sankyo's 4568.T breast cancer treatment Enhertu for NHS use, in its first major decision since the UK revised drug cost-effectiveness thresholds.

  • British Prime Minister Andy Burnham is considering reforms to England's water industry that would give mayors and other local leaders greater oversight role over regional water companies.

  • Clearlake Capital has agreed to buy the stakes held by Mark Walter and Todd Boehly in Chelsea FC in a deal valuing the club at about £5 billion ($6.68 billion), including debt.

  • Vodafone VOD.L is set to miss out on more than €1 billion ($1.15 billion) in potential earnings after Patrick Drahi sold his stake in broadband venture OXG to Societe Generale SOGN.PA.

($1 = 0.7481 pounds)

($1 = 0.8728 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.